On 11 June 2024, Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study confirming that the primary endpoint was met and no new safety concerns emerged. Read the full press release.
On 11 June 2024, Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study confirming that the primary endpoint was met and no new safety concerns emerged. Read the full press release.